JORVEC CORP. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases w
JORVEC CORP. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $155,041
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- FL
- Period
- —
Description
DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeuticapproaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroretinogram (PERG) is the only established tool to monitor RGC health in vivo in humans and experimental models ofoptic nerve diseases. The monitoring of PERG responses can potentially provide earlier detection of degenerative retinal disorders such as glaucoma, allowing for treatment paradigms to be initiated before irreversible functional vision loss has occurred.A critical barrier to the widespread adoption of PERG for research and clinical use is the lack of availability of an easy-to-use, turnkey device for recording and data analysis. The goal of the proposed project is to produce commercially available